AEterna Zentaris (TSX:AEZS) Gross Margin % : 54.94% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. AEterna Zentaris's Gross Profit for the three months ended in Dec. 2023 was C$0.09 Mil. AEterna Zentaris's Revenue for the three months ended in Dec. 2023 was C$0.16 Mil. Therefore, AEterna Zentaris's Gross Margin % for the quarter that ended in Dec. 2023 was 54.94%.

The historical rank and industry rank for AEterna Zentaris's Gross Margin % or its related term are showing as below:

TSX:AEZS' s Gross Margin % Range Over the Past 10 Years
Min: 22.97 Med: 93.62 Max: 98.29
Current: 95.1

During the past 13 years, the highest Gross Margin % of AEterna Zentaris was 98.29%. The lowest was 22.97%. And the median was 93.62%.

TSX:AEZS's Gross Margin % is ranked better than
93.06% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs TSX:AEZS: 95.10

AEterna Zentaris had a gross margin of 54.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for AEterna Zentaris was 16.90% per year.

AEterna Zentaris Gross Margin % Historical Data

The historical data trend for AEterna Zentaris's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Gross Margin % Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

22.97

36.55

98.29

97.22

95.06

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															97.96	99.18	93.80	-275.00	54.94

Competitive Comparison of AEterna Zentaris's Gross Margin %

For the Biotechnology subindustry, AEterna Zentaris's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Gross Margin % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Gross Margin % falls into.

AEterna Zentaris Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

AEterna Zentaris's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	5.7	/	6.035
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(6.035 - 0.298)	/	6.035
	=	95.06 %

AEterna Zentaris's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.1	/	0.162
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.162 - 0.073)	/	0.162
	=	54.94 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

AEterna Zentaris (TSX:AEZS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

AEterna Zentaris had a gross margin of 54.94% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

AEterna Zentaris Gross Margin % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.